Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 FDA Approves Next-Generation Cardiac Device From BioTelemetry Inc. - Medical Product Outsourcing
OEM News

FDA Approves Next-Generation Cardiac Device From BioTelemetry Inc.

The new device was developed in partnership with Belgium-based IMEC.

BioTelemetry Inc., a wireless medical technology company focused on the delivery of health information, has received U.S. Food and Drug Administration (FDA) 510(k) clearance of its next-generation Mobile Cardiac Outpatient Telemetry device, the MCOT Patch. The patch is a four-lead, two-channel system which provides the same technology as the current MCOT, in a more convenient form factor. The MCOT devices, through the use of a proprietary algorithm, offer the most accurate remote arrhythmia detection available on the market, according to BioTelemetry. 
 
The new device was developed in partnership with Belgium-based IMEC, a leading developer of nanoelectronics. The system also incorporates proprietary patch technology the company recently acquired from DELTA Danish Electronics, Light and Acoustic. The company expects the MCOT Patch to be commercially available later this year.
 
“We are extremely excited to announce this latest milestone in the evolution of our MCOT technology,” said Joseph H. Capper, president and CEO of BioTelemetry. “Validated by numerous clinical publications and abstracts, MCOT is widely recognized among remote monitoring options as the ‘gold standard’ in terms of sensitivity and accuracy in the detection of arrhythmias such as atrial fibrillation. The MCOT Patch incorporates this same unmatched detection capability into a light-weight, easy-to-use patch form factor, which we believe will lead to higher utilization. Moreover, due to its advanced capabilities and flexible design, our new sensor is also anticipated to have commercially viable applications in other areas of healthcare. The introduction of the new system demonstrates our ongoing commitment to reaching as many patients as possible with our life-saving technology and service.”
 
BioTelemetry Inc., formerly known as CardioNet Inc.,  provides cardiac monitoring services, original equipment manufacturing with a primary focus on cardiac monitoring devices, and centralized cardiac core laboratory services. The company is based in Malvern, Pa.

Add us as a preferred source on Google

Get the latest Medical Product Outsourcing news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Medical Product Outsourcing Newsletters